Spring 2020 LipidSpin Articles | National Lipid Association Online

ANTONIO M. GOTTO, JR., MD, DPhil, FNLA	Letter from the NLA President: Your NLA New Year’s Check-In & Check List I would like to wish everyone a Happy New Year! With the new year upon us and being more than halfway through my term as President, I wanted to thank the membership for the opportunity to provide a reminder of a few key initiatives of the NLA and make sure you complete your 2020 NLA checklist: • Pay dues – lipid.org/dues/payment • Recruit a colleague –... more
ANN LIEBESKIND, MD, FAAP, FNLA	From the MWLA President: Branching Out: The Tree of Lipidology Continues to Grow While expertise in lipids management has evolved over many decades, our field of lipidology truly took flight in 2006 with the American Board of Clinical Lipidology certification process. Since those early days, we have slowly but steadily raised awareness of the value of the care we provide as lipid specialists. It is likely that each and every one of you has had to explain what a lipid specialist is, or does, more than once in your career. While our role in treating lipid disorders is... more
KAYE-EILEEN WILLARD, MD, FNLA	Editor’s Corner: Don’t Miss the Forest for the Trees “People who believe they are ignorant of nothing have neither looked for nor stumbled upon the boundary between what is known and unknown in the universe” — Neil deGrasse Tyson It is a privilege as the co-editor of the LipidSpin to write the Editor’s Corner for the Midwest (MWLA) edition of the journal. Our membership has come to expect a high calibre, informative and instructive journal to help them with their daily practice of clinical lipidology. Consistent with a... more
MAYA BALAKRISHNAN, MD DAVID R. NEFF, DO	Clinical Feature: Nonalcoholic Fatty Liver Disease: The Hepatic Complication of Metabolic Dysmetabolism Nonalcoholic fatty liver disease (NAFLD) is the main hepatic complication of obesity, diabetes and metabolic syndrome. Its prevalence has risen dramatically since 1980, when it was a perplexing and sporadically-observed disease as first reported by Ludwig and colleagues (1), to a current estimated 25% global prevalence.(2) NAFLD represents the leading cause of chronic liver disease and is the second leading indication for liver transplantation in the United States.(3) Its rise... more
KRISTEN A. MARTEN, DO AMY L. PETERSON, MD	EBM Tools for Practice: Pediatric Metabolic Syndrome: Difficult to Define, Important to Treat Although there is debate over the definition of metabolic syndrome in adults, the picture is even more clouded in pediatrics. Metabolic syndrome in adults is defined as having at least three of the following five cardiometabolic risk factors: hyperglycemia, increased central adiposity, elevated triglycerides, decreased HDL cholesterol and elevated blood pressure.(1) In pediatrics, there have been up to 40 definitions of metabolic syndrome proposed. The most commonly used definitions are... more
SARA LYNN PETERSON, PharmD	Lipid Luminations: Risk Reduction: DECLARE-TIMI 58 Outcomes Results from multiple trials prompted the Food and Drug Administration’s (FDA) approval of empagliflozin (Jardiance) for reducing cardiovascular (CV) death and canagliflozin (Invokana) for reducing CV death and CV events, in patients with cardiovascular disease and type II diabetes (T2D).(1-6) The FDA’s expanded approval of empagliflozin and canagliflozin led to the American College of Cardiology (ACC) and the American Diabetes Association (ADA) incorporating sodium–glucose... more
MRINALI SHETTY, MD DAVID DAVIDSON, MD, FACC, FNLA	Practical Pearls: Recognition and Treatment For Fabry’s Disease and Morquio A Syndrome Fabry’s Disease and Morquio A syndrome are two rare genetic diseases that lead to a diverse series of problems including cardiovascular.(1,30) Until recently, treatment options have been limited to treat these conditions. Now that there are available therapies to help improve quality and quantity of life, (20,46) it is important to be able to recognize these conditions in clinical practice to help initiate treatment earlier. The goal of this “Practical Pearl” is to help identify these... more
ABIGAIL F. RABATIN, PharmD, BCACP, CLS KELLY M. BARTSCH, PharmD, BCPS, CLS ELISA M. BADDOUR, PharmD, BCACP LAXMI S. MEHTA, MD, FACC	Case Study: Elevated LDL Secondary to Multiple Myeloma Introduction Elevated cholesterol is a well-known and modifiable risk factor for cardiovascular disease. Hyperlipidemia due to secondary causes is common and should be evaluated as part of treatment. Potential secondary causes include diabetes mellitus, excessive alcohol intake, cholestatic liver disease, hypothyroidism, chronic kidney disease, nephrotic syndrome and various classes of medications.(1) Multiple myeloma is a malignant neoplasm characterized by proliferation... more
ANN LIEBESKIND, MD, FAAP, FNLA	Chapter Update: The MWLA Three-Year Plan The Midwest Lipid Association Chapter started the fall with our co-sponsored Clinic Lipid Update in Minneapolis in September. It was great to see many familiar NLA member colleagues as well as new attendees. As part of the MWLA’s goals for this year, we are finalizing a three-year strategic plan. An important step was to create a mission statement. The mission of the Midwest Lipid Association is to support the National Lipid Association in growing the... more
KAVEH REZAEI BOOKANI, MD DAVID DAVIDSON, MD, FACC, FNLA MARLYS L. KOSCHINSKY, PhD, FNLA	Specialty Corner: Lipid Metabolism and Cardiovascular Disease in Patients with Renal Disease Reduced estimated glomerular filtration rate (GFR) and chronic kidney disease (CKD) are also independently associated with the risk of death and cardiovascular (CV) events in community.(3) When compared to the general population, patients with CKD have a distinct lipid profile which involves alterations in different lipoprotein classes and shows considerable variations depending on the stage of CKD.(4) Although very complex, the most important characteristics of this uremic lipid profile can... more
SASHA DE JESUS, MD MERLE MYERSON, MD, EdD, FACC, FNLA EUGENIA GIANOS, MD, FACC, FASE, FNLA	Women’s Health: Guidelines for Lipid-Lowering in Women – What Have we Learned? Cardiovascular disease (CVD) remains the leading cause of death for women in the United States.(1) Unique factors affecting a woman’s health contribute significantly to CVD risk, but historically were not always represented in major guidelines. Some of these factors include hormonal changes, the presence of gender-specific risk factors and comorbidities more frequently seen in women (e.g. rheumatoid arthritis and systemic lupus erythematosus). Although women typically present with heart... more
DOUGLAS JACOBY, MD, FNLA MICHAEL AYERS, MD	Backspin: New Cholesterol Guidelines: Coronary Artery Calcium Scores a Win In October of 2018, the American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with the National Lipid Association and other organizations, published evidence-based guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD).(1) Along with the guidelines, there was a Special Report summarizing the rationale and evidence base for the current quantitative risk assessment tools.(2) These newest iterations... more
KEVIN C. MAKI, PhD, CLS, FACN, FNLA MARY R. DICKLIN, PhD MAYA BALAKRISHNAN, MD DAVID R. NEFF, DO	Guest Editorial: Postprandial Dysmetabolism: Understanding the Impact of Elevated Postprandial Glucose and Triglycerides with the Potential to Prevent or Intervene Early In 2019, the Centers for Disease Control and Prevention reported that prevalence for both obesity and overweight have continued to rise over the last eight years and are at an all-time high for adults and adolescents.(1) Approximately two-thirds of US adults are either obese (31%) or overweight (35%). Approximately one-third of US adolescents in grades 9-12 are obese (15%) or overweight (16%). Obesity in childhood and young adulthood is a predictor of weight difficulties in middle age and... more